Pimecrolimus in the treatment of atopic dermatitis
Article Sidebar
Published:
Jul 19, 2012
Keywords:
pimecrolimus, atopic dermatitis, treatment
Main Article Content
Abstract
Pimecrolimus is a topical calcineurin inhibitor in a form of 1% cream used for the treatment of patients with atopic dermatitis (AD) of mild and moderate intensity. It has an anti-inflammatory effect by inhibiting the synthesis and release of cytokines by T cells, mast cells and neutrophils. It likewise has an affect on the expression of genes responsible for the proper function of the epidermal barrier. We present the literature data and clinical observations concerning pimecrolimus treatment and prevention of exacerbation of atopic dermatitis symptoms. It was shown that pimecrolimus is an alternative choice of treatment for patients for whom therapy with topical corticisteroids are not possible nor recommended. We also present casuistic study reports, in which anti-inflammatory and immunomodulatory effects of pimecrolimus were used for the treatment of other skin diseases.
Downloads
Download data is not yet available.
Article Details
How to Cite
Owczarek , W. (2012). Pimecrolimus in the treatment of atopic dermatitis. Alergoprofil, 8(2), 4-8. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/728
Issue
Section
Article
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Arellano F., Wentworth C.E., Arana A., Fernandez C., Paul C.E.: Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J. Invest. Dermatol. 2007, 127: 808-816.
2. Bagan J., Compilato D., Paderni C., Panzarella V., Picciotti M., Lorenzini G., Di Fede O.: Topical therapies for Oral Lichen Planus management and their efficacy: a narrative review. Curr. Pharm. Des. 2012 [online].
3. Büchau A.S., Schauber J., Hultsch T., Stuetz A., Gallo R.L.: Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J. Invest. Dermatol. 2008, 128(11): 2646-54.
4. Campanati A., Brandozzi G., Giangiacomi M., Simonetti O., Marconi B., Offidani A.M.: Lichen striatus in adults and pimecrolimus: open, off-label clinical study. Int. J. Dermatol. 2008, 47(7): 732-6.
5. Chams-Davatchi C., Barikbin B., Shahram F., Nadji A., Moghaddassi M., Yousefi M., Davatchi F.: Pimecrolimus versus placebo in genital aphthous ulcers of Behcet‘s disease: a randomized double-blind controlled trial. Int. J. Rheum. Dis. 2010, 13(3): 253-8.
6. Cheng S., Kirtschig G., Cooper S., Thornhill M., Leonardi-Bee J., Murphy R.: Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst. Rev. 2012, 2: CD008092.
7. Chi C.C., Kirtschig G., Baldo M., Brackenbury F., Lewis F., Wojnarowska F.: Topical interventions for genital lichen sclerosus. Cochrane Database Syst. Rev. 2011, 12: CD008240.
8. Delgado L., Brandt H.R., Ortolan D.G., Patriota R.C., Criado P.R., Belda Junior W.: Zoon‘s plasma cell balanitis: a report of two cases treated with pimecrolimus. An. Bras. Dermatol. 2011, 86(4 Suppl. 1): S35-8.
9. Eichenfield L.F., Lucky A.W., Boguniewicz M., Langley R.G., Cherill R., Marshall K., Bush C., Graeber M.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 2002, 46(4): 495-504.
10. Farshi S., Mansouri P.: Letter: Generalized lichen nitidus successfully treated with pimecrolimus 1 percent cream. Dermatol. Online J. 2011, 17(7): 11.
11. Frew J.W., Martin L.K., Murrell D.F.: Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol. Clin. 2011, 29(4): 599-606.
12. Grzanka A., Zebracka-Gala J., Rachowska R., Bozek A., Kowalska M., Jarzab J.: The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp. Dermatol. 2012, 21(3): 184-8.
13. Hagstroemer L., Ye W., Nyren O., Emtestam L.: Incidence of cancer among patients with atopic dermatitis. Arch. Dermatol. 2005, 141(9): 1123-7.
14. Ho V.C., Gupta A., Kaufmann R., Todd G., Vanaclocha F., Takaoka R., Fölster-Holst R., Potter P., Marshall K., Thurston M., Bush C., Cherill R.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 2003, 142(2): 155-62.
15. Hultsch T., Kapp A., Spergel J.: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005, 211(2): 174-87.
16. Kaufmann R., Bieber T., Helgesen A.L., Andersen B.L., Luger T., Poulin Y., Al-Hafidh J., Paul C.: Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006, 61(3): 375-81.
17. Khondker L., Wahab M.A., Khan S.I.: Efficacy of topical application of pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh. Med. J. 2012, 21(2): 259-64.
18. Kim J.E., Jeong M.G., Lee H.E., Ko J.Y., Ro Y.S.: Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann. Dermatol. 2011, 23(3): 348-51.
19. Kim M.B., Kim G.W., Park H.J., Kim H.S., Chin H.W., Kim S.H., Kim B.S., Ko H.C.: Pimecrolimus 1% cream for the treatment of rosacea. J. Dermatol. 2011, 38(12): 1135-9.
20. Köse O., Arca E., Kurumlu Z.: Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J. Dermatolog. Treat. 2010, 21(3): 133-9.
21. Lee Y., Choi E.H.: Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae. J. Dermatol. 2011, 38(11): 1072-5.
22. Ma Z., Tovar J.P., Kwong K.Y., Paek D.: Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int. Arch. Allergy Immunol. 2010, 153(4): 413-8.
23. Meurer M., Fartasch M., Albrecht G., Vogt T., Worm M., Ruzicka T., Altmeyer P.J., Schneider D., Weidinger G., Braeutigam M.: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004, 208(4): 365-72.
24. Meurer M., Lubbe J., Kapp A., Schneider D.: The role of pimecrolimus cream 1% (Elidel) in managing adult atopic eczema. Dermatology 2007, 215(Suppl. 1): 18-26.
25. Milcic D., Nikolic M.: Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. Australas. J. Dermatol. 2012, 53(2): e34-5.
26. Neczyporenko F., Blondeel A.: Allergic contact dermatitis to Elidel cream itself? Contact Dermatitis 2010, 63(3): 171-2.
27. Papp K., Staab D., Harper J., Potter P., Puig L., Ortonne J.P., Molloy S., Barbier N., Paul C.: Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int. J. Dermatol. 2004, 43(12): 978-83.
28. Pérez-Carmona L., Fleta-Asín B., Moreno-García-DelReal C., Jaén-Olasolo P.: Successful treatment of Darier‘s disease with topical pimecrolimus. Eur. J. Dermatol. 2011, 21(2): 301-2.
29. Queille-Roussel C.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. 2001, 144: 507-513.
30. Rigopoulos D., Prantsidis A., Christofidou E., Ioannides D., Gregoriou S., Katsambas A.: Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br. J. Dermatol. 2005, 152(6): 1364-5.
31. Spergel J.M.: Immunology and treatment of atopic dermatitis. Am. J. Clin. Dermatol. 2008, 9(4): 233-244.
32. Spergel J.M.: Pimecrolimus cream in the management of patients with atopic eczema. Clin. Cosmet. Investig. Dermatol. 2009, 2: 85-93.
33. Tatlican S., Eren C., Eskioglu F.: Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile. J. Dermatolog. Treat. 2009, 20(4): 198-202.
34. Tchernev G., Cardoso J.C.: Familial benign chronic pemphigus (Hailey-Hailey Disease): use of topical immunomodulators as a modern treatment option. Rev. Med. Chil. 2011, 139(5): 633-7.
35. Thaçi D., Salgo R.: The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatoven. APA 2007, 16(2): 58-62.
36. Ucak H., Kandi B., Cicek D., Halisdemir N., Dertlýođlu S.B.: The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J. Dermatolog. Treat. 2011. https://doi.org/10.3109/09546634.2011.590788.
37. Wahn U., Bos J.D., Goodfield M., Caputo R., Papp K., Manjra A., Dobozy A., Paul C., Molloy S., Hultsch T., Graeber M., Cherill R., de Prost Y.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitisin children. Pediatrics 2002, 110(1 Pt 1): e2.
38. Wang H., Diepgen T.L.: Atopic dermatitis and cancer risk. Br. J. Dermatol. 2006, 154(2): 205-10.
39. Wohlrab J.: Calcineurin inhibitors for topical therapy in psoriasis. Hautarzt 2006, 57(8): 685-9.
40. Yan A.C., Honig P.J., Ming M.E., Weber J., Shah K.N.: The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch. Dermatol. 2010, 146(1): 57-62.
2. Bagan J., Compilato D., Paderni C., Panzarella V., Picciotti M., Lorenzini G., Di Fede O.: Topical therapies for Oral Lichen Planus management and their efficacy: a narrative review. Curr. Pharm. Des. 2012 [online].
3. Büchau A.S., Schauber J., Hultsch T., Stuetz A., Gallo R.L.: Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J. Invest. Dermatol. 2008, 128(11): 2646-54.
4. Campanati A., Brandozzi G., Giangiacomi M., Simonetti O., Marconi B., Offidani A.M.: Lichen striatus in adults and pimecrolimus: open, off-label clinical study. Int. J. Dermatol. 2008, 47(7): 732-6.
5. Chams-Davatchi C., Barikbin B., Shahram F., Nadji A., Moghaddassi M., Yousefi M., Davatchi F.: Pimecrolimus versus placebo in genital aphthous ulcers of Behcet‘s disease: a randomized double-blind controlled trial. Int. J. Rheum. Dis. 2010, 13(3): 253-8.
6. Cheng S., Kirtschig G., Cooper S., Thornhill M., Leonardi-Bee J., Murphy R.: Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst. Rev. 2012, 2: CD008092.
7. Chi C.C., Kirtschig G., Baldo M., Brackenbury F., Lewis F., Wojnarowska F.: Topical interventions for genital lichen sclerosus. Cochrane Database Syst. Rev. 2011, 12: CD008240.
8. Delgado L., Brandt H.R., Ortolan D.G., Patriota R.C., Criado P.R., Belda Junior W.: Zoon‘s plasma cell balanitis: a report of two cases treated with pimecrolimus. An. Bras. Dermatol. 2011, 86(4 Suppl. 1): S35-8.
9. Eichenfield L.F., Lucky A.W., Boguniewicz M., Langley R.G., Cherill R., Marshall K., Bush C., Graeber M.: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 2002, 46(4): 495-504.
10. Farshi S., Mansouri P.: Letter: Generalized lichen nitidus successfully treated with pimecrolimus 1 percent cream. Dermatol. Online J. 2011, 17(7): 11.
11. Frew J.W., Martin L.K., Murrell D.F.: Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol. Clin. 2011, 29(4): 599-606.
12. Grzanka A., Zebracka-Gala J., Rachowska R., Bozek A., Kowalska M., Jarzab J.: The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions. Exp. Dermatol. 2012, 21(3): 184-8.
13. Hagstroemer L., Ye W., Nyren O., Emtestam L.: Incidence of cancer among patients with atopic dermatitis. Arch. Dermatol. 2005, 141(9): 1123-7.
14. Ho V.C., Gupta A., Kaufmann R., Todd G., Vanaclocha F., Takaoka R., Fölster-Holst R., Potter P., Marshall K., Thurston M., Bush C., Cherill R.: Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 2003, 142(2): 155-62.
15. Hultsch T., Kapp A., Spergel J.: Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005, 211(2): 174-87.
16. Kaufmann R., Bieber T., Helgesen A.L., Andersen B.L., Luger T., Poulin Y., Al-Hafidh J., Paul C.: Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006, 61(3): 375-81.
17. Khondker L., Wahab M.A., Khan S.I.: Efficacy of topical application of pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh. Med. J. 2012, 21(2): 259-64.
18. Kim J.E., Jeong M.G., Lee H.E., Ko J.Y., Ro Y.S.: Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann. Dermatol. 2011, 23(3): 348-51.
19. Kim M.B., Kim G.W., Park H.J., Kim H.S., Chin H.W., Kim S.H., Kim B.S., Ko H.C.: Pimecrolimus 1% cream for the treatment of rosacea. J. Dermatol. 2011, 38(12): 1135-9.
20. Köse O., Arca E., Kurumlu Z.: Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J. Dermatolog. Treat. 2010, 21(3): 133-9.
21. Lee Y., Choi E.H.: Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae. J. Dermatol. 2011, 38(11): 1072-5.
22. Ma Z., Tovar J.P., Kwong K.Y., Paek D.: Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int. Arch. Allergy Immunol. 2010, 153(4): 413-8.
23. Meurer M., Fartasch M., Albrecht G., Vogt T., Worm M., Ruzicka T., Altmeyer P.J., Schneider D., Weidinger G., Braeutigam M.: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004, 208(4): 365-72.
24. Meurer M., Lubbe J., Kapp A., Schneider D.: The role of pimecrolimus cream 1% (Elidel) in managing adult atopic eczema. Dermatology 2007, 215(Suppl. 1): 18-26.
25. Milcic D., Nikolic M.: Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. Australas. J. Dermatol. 2012, 53(2): e34-5.
26. Neczyporenko F., Blondeel A.: Allergic contact dermatitis to Elidel cream itself? Contact Dermatitis 2010, 63(3): 171-2.
27. Papp K., Staab D., Harper J., Potter P., Puig L., Ortonne J.P., Molloy S., Barbier N., Paul C.: Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis. Int. J. Dermatol. 2004, 43(12): 978-83.
28. Pérez-Carmona L., Fleta-Asín B., Moreno-García-DelReal C., Jaén-Olasolo P.: Successful treatment of Darier‘s disease with topical pimecrolimus. Eur. J. Dermatol. 2011, 21(2): 301-2.
29. Queille-Roussel C.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. 2001, 144: 507-513.
30. Rigopoulos D., Prantsidis A., Christofidou E., Ioannides D., Gregoriou S., Katsambas A.: Pimecrolimus 1% cream in the treatment of disseminated granuloma annulare. Br. J. Dermatol. 2005, 152(6): 1364-5.
31. Spergel J.M.: Immunology and treatment of atopic dermatitis. Am. J. Clin. Dermatol. 2008, 9(4): 233-244.
32. Spergel J.M.: Pimecrolimus cream in the management of patients with atopic eczema. Clin. Cosmet. Investig. Dermatol. 2009, 2: 85-93.
33. Tatlican S., Eren C., Eskioglu F.: Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile. J. Dermatolog. Treat. 2009, 20(4): 198-202.
34. Tchernev G., Cardoso J.C.: Familial benign chronic pemphigus (Hailey-Hailey Disease): use of topical immunomodulators as a modern treatment option. Rev. Med. Chil. 2011, 139(5): 633-7.
35. Thaçi D., Salgo R.: The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update. Acta Dermatoven. APA 2007, 16(2): 58-62.
36. Ucak H., Kandi B., Cicek D., Halisdemir N., Dertlýođlu S.B.: The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata. J. Dermatolog. Treat. 2011. https://doi.org/10.3109/09546634.2011.590788.
37. Wahn U., Bos J.D., Goodfield M., Caputo R., Papp K., Manjra A., Dobozy A., Paul C., Molloy S., Hultsch T., Graeber M., Cherill R., de Prost Y.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitisin children. Pediatrics 2002, 110(1 Pt 1): e2.
38. Wang H., Diepgen T.L.: Atopic dermatitis and cancer risk. Br. J. Dermatol. 2006, 154(2): 205-10.
39. Wohlrab J.: Calcineurin inhibitors for topical therapy in psoriasis. Hautarzt 2006, 57(8): 685-9.
40. Yan A.C., Honig P.J., Ming M.E., Weber J., Shah K.N.: The safety and efficacy of pimecrolimus, 1%, cream for the treatment of Netherton syndrome: results from an exploratory study. Arch. Dermatol. 2010, 146(1): 57-62.